Intervention not reported
Overall survival Hazard ratio · patients with resectable thoracic esophageal cancer
The intervention probably leads to lower overall survival Hazard ratio (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival [range of median · patients with APL in first complete remission
The intervention may leads to lower overall survival [range of median (low certainty).
1 finding from 1 review
no estimate extracted
892 participants
Low
Intervention not reported
Overall survival [range of median · patients with APL in first complete remission
The intervention probably leads to lower overall survival [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
632 participants
Moderate
Intervention not reported
Overall survival [range of median · patients with APL in first complete remission
The intervention probably leads to lower overall survival [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
1033 participants
Moderate
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether docetaxel changes overall survival ‐ Other comparisons compared with non‐docetaxel‐containing regimens (very low certainty).
1 finding from 1 review
Overall survival with intravenous platinum (i.e. mortality/number of participants deceased) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in overall survival with intravenous platinum (i.e. mortality/number of… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Docetaxel probably leads to lower overall survival ‐ Additive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival (time interval between enrolment in the study and death of the person from any cause) · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
5‐year overall survival rate (3 to 6 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year overall survival rate (3 to 6 yr) (low certainty).
1 finding from 1 review
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus taxane · advanced pancreatic cancer
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus taxane compared with gemcitabine alone (high certainty).
1 finding from 1 review
Intervention not reported
Mortality (instead of overall survival)[2] · People with AML in first complete remission
The intervention showed no clear difference in mortality (instead of overall survival)[2] (moderate certainty).
1 finding from 1 review
Intervention not reported
10‐year overall survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 10‐year overall survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer
Docetaxel showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
Intervention not reported
3‐year overall survival rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year overall survival rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
All‐cause mortality: 2‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review